In this trial, the investigators will recruit 60 participants diagnosed with HFrEF (NYHA class II-IV) and assign participants to two groups to receive standard medication therapy with or without vericiguat (target 5mg qd) for 3 months. Before and after the 3-month medication therapy, patients will receive cardiac magnetic resonance (CMR) assessment. The primary endpoint is the change in extracellular volume (ECV) measured by CMR.
Vericiguat is a new medication therapy choice for the patients with heart failure with reduced ejection fraction (HFrEF), in the latest trial, it met the expectation to reduce incidence of death from cardiovascular causes or hospitalization for heart failure among HFrEF patients. Myocardial fibrosis as a pathological change in heart failure, it contributes to left ventricular dysfunction leading to development of the disease, experimental studies have showed the potential prevention, or even reversal effect of sGC stimulators in left ventricular hypertrophy and fibrosis. Our study is a prospective controlled clinical trial aim to verify the anti-myocardial fibrosis effect of vericiguat in heart failure with reduced ejection fraction.